Login / Signup

Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting - A disproportionality analysis.

Christopher A GravelDaniel KrewskiDonald R MattisonFranco MomoliAntonios Douros
Published in: British journal of clinical pharmacology (2023)
There was no increased risk of myotoxicity reporting associated with concomitant use of SGLT2i and statins or for specific drug pairs.
Keyphrases
  • adverse drug
  • cardiovascular disease
  • drug induced